“With the approval of 177Lu-PSMA-617, a new class of therapeutics is available to patients with prostate cancer. We look forward to the potential use of PSMA radionuclide therapy in pre-chemotherapy mCRPC or other settings pending the full results of ongoing trials,” noted the authors.
The full consensus statement on patient selection and appropriate use of 177Lu-PSMA-617 radionuclide therapy can be viewed on SNMMI’s website.
The authors of “SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy” include Thomas A. Hope, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; Emmanuel S. Antonarakis, 2 University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota; Lisa Bodei, Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; Jeremie Calais, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; Amir Iravani, Department of Radiology, University of Washington, Seattle, Washington; Heather Jacene, Department of Radiology, Brigham and Women’s Hospital, and Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts; Phillip J. Koo, Banner M.D. Anderson Cancer Center, Phoenix, Arizona; Alicia K. Morgans and Mary-Ellen Taplin, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Joseph R. Osborne, Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, New York; Scott T. Tagawa, Department of Medicine, Weill Cornell Medical College, New York, New York; Oliver Sartor, Mayo Clinic, Rochester, Minnesota; and Michael J. Morris, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Back to HCB News
